Scholarlink

<p>Psoriasis is a chronic inflammatory skin disorder driven by epidermal hyperplasia, immune infiltration, and pathological angiogenesis. PAP‑1, a selective Kv1.3 channel blocker, exhibits therapeutic potential, though its underlying mechanisms remain incompletely understood. Here, we show that both preventive and therapeutic administration of PAP‑1 markedly attenuates imiquimod (IMQ)-induced psoriasis‑like skin lesions and reduces splenomegaly in male rats. RNA sequencing revealed that PAP-1 downregulated genes associated with inflammation and angiogenesis, accompanied by decreased levels of pro-inflammatory cytokines and vascular markers. PAP-1 also inhibited VEGF-A-induced HUVEC proliferation, migration, invasion, and tube formation. Mechanistically, PAP-1 not only blocked Kv1.3 currents, but also suppressed Kv1.3 expression in the skin of IMQ-induced psoriasis-like male rats and VEGF-A-induced HUVECs. Cryo-EM structural analysis revealed that PAP-1 binds within the central cavity of Kv1.3, beneath the selectivity filter, in an inactivated state. These results establish that preventive and therapeutic PAP-1 alleviates psoriasis-like dermatitis via dual anti-inflammatory and anti-angiogenic mechanisms, supporting its further therapeutic development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Kv1.3 blocker PAP‑1 alleviates psoriasis‑like dermatitis in rats via suppressing inflammation and angiogenesis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Feng Yao,
  • Yong Zhang,
  • Yanmin Zheng,
  • Renpeng Zhou,
  • Tianqi Liu,
  • Lulu Wang,
  • Gengxin Wang,
  • Qiuxia Yu,
  • Demeng Sun,
  • Sanling Liu,
  • Changlin Tian,
  • Wei Hu

摘要

Psoriasis is a chronic inflammatory skin disorder driven by epidermal hyperplasia, immune infiltration, and pathological angiogenesis. PAP‑1, a selective Kv1.3 channel blocker, exhibits therapeutic potential, though its underlying mechanisms remain incompletely understood. Here, we show that both preventive and therapeutic administration of PAP‑1 markedly attenuates imiquimod (IMQ)-induced psoriasis‑like skin lesions and reduces splenomegaly in male rats. RNA sequencing revealed that PAP-1 downregulated genes associated with inflammation and angiogenesis, accompanied by decreased levels of pro-inflammatory cytokines and vascular markers. PAP-1 also inhibited VEGF-A-induced HUVEC proliferation, migration, invasion, and tube formation. Mechanistically, PAP-1 not only blocked Kv1.3 currents, but also suppressed Kv1.3 expression in the skin of IMQ-induced psoriasis-like male rats and VEGF-A-induced HUVECs. Cryo-EM structural analysis revealed that PAP-1 binds within the central cavity of Kv1.3, beneath the selectivity filter, in an inactivated state. These results establish that preventive and therapeutic PAP-1 alleviates psoriasis-like dermatitis via dual anti-inflammatory and anti-angiogenic mechanisms, supporting its further therapeutic development.